" class="no-js "lang="en-US"> Granular Therapeutics Accelerate Mast Cell Disease Treatment
Friday, April 12, 2024

Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases

Granular Therapeutics, a private biotech company specialising in precision biologic therapies for treating mast cell driven disease, today announces clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies. Granular has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development.

Since starting work on these concepts in 2019 with backing from Medicxi, Granular has gained a deep understanding of the biology of mast cells and their role in chronic inflammatory diseases. It has developed a pipeline of next-generation approaches that selectively target mast cells. This approach by Granular can drive direct and specific mast cell inhibition, avoid systemic toxicity and enable safe chronic dosing for mast cell driven disease such as chronic urticaria or systemic mastocytosis.

Brian Kim, Scientific Advisory Board member of Granular Therapeutics, remarked: “Recent data in the field of mast cell driven diseases like Urticaria have shown that tremendous efficacy can be attained, but safety concerns still remain, especially in chronic disease settings. Granular offers a next generation modality that offers the promise of increased selectivity and safety.”

As Granular embarks on the development of its mast cell targeting pipeline of therapies towards clinical phases, it has appointed a dermatology expert, Dr Thibaud Portal, as Chief Executive Officer. Thibaud Portal is a dermatology specialist who was previously Head of Prescription Medicines business and strategy at Galderma SA and is also co-founder of multiple dermatology focused start-up companies. Dr Jonny Finlay, who co-founded Granular and oversaw the discovery phases, will continue to advise the company and will serve on its Board of Directors.

Thibaud Portal, Chief Executive Officer of Granular Therapeutics, commented: “I am honored and delighted to join the Granular team. Selective mast cell targeting offers outstanding opportunities to address a range of disease indications with a high unmet medical need. I believe this new approach is a significant advancement in the field of chronic inflammatory diseases and that Granular has most exciting pipeline in the field.”

Jonny Finlay, Co-founder and Member of the Board of Directors of Granular Therapeutics said: “Finalising the selection of our first clinical candidate is a critical milestone for our company. It is the ideal time to add new competences to the company in order to optimise the positioning of Granular’s innovative portfolio of exciting assets across high priority therapeutic areas in the field of chronic inflammatory diseases.”

Francesco De Rubertis, Chairman of Granular Therapeutics, added: “We are pleased to welcome Thibaud to Granular’s leadership team at this pivotal time of Company growth. As we approach important inflection points, Thibaud’s expertise and knowledge will be invaluable in making defining decisions for the future of our innovative programmes.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more